First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictorRuth Plummer, Debashis Sarker|British Journal of Cancer|2020Cited by 76
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Clinical Cancer Research|2022Cited by 41
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Udai Banerji, Ruth Plummer et al.|British Journal of Cancer|2023Cited by 36
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Hendrik‐Tobias Arkenau et al.|Journal of Clinical Oncology|2019Cited by 31
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.Udai Banerji, Robert H. Jones, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 20